---
title: "UltraGreen.ai gains Singapore approval for Verdye in regional push"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285153690.md"
description: "UltraGreen.ai has received regulatory approval in Singapore for Verdye, facilitating its expansion in Southeast Asia. This approval allows access to Singapore's healthcare system, enhancing commercialization efforts and partnerships with local hospitals. Verdye is utilized in fluorescence-guided surgeries across various medical fields. CEO Ravi Sajwan emphasized Singapore's strategic importance in clinical adoption in the region. Verdye is already approved in 41 countries, and the company is also expanding in the Philippines following its recent IPO."
datetime: "2026-05-05T04:40:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285153690.md)
  - [en](https://longbridge.com/en/news/285153690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285153690.md)
---

# UltraGreen.ai gains Singapore approval for Verdye in regional push

**The regulatory clearance anchors UltraGreen.ai's Southeast Asia expansion.**

UltraGreen.ai has secured regulatory approval in Singapore for Verdye, or indocyanine green for injection, which will support its expasion in Southeast Asia.

In a press release, the company said the approval gives the company access to Singapore’s healthcare system, noting Singapore acts as a centre for clinical practice and regional influence in healthcare adoption.

The approval also supports its commercialisation efforts and partnerships with hospitals and healthcare institutions in the city-state.

Verdye is used in fluorescence-guided surgery with indocyanine green, applied in oncology, colorectal, reconstructive, and vascular procedures.

UltraGreen.ai develops a fluorescence-guided surgery platform combining pharmaceutical products, imaging hardware, and artificial intelligence-based data tools for surgical decision-making and procedural standardisation.

The company said the platform supports wider adoption of fluorescence-guided surgery across procedures.

Ravi Sajwan, CEO of UltraGreen.ai, said Singapore serves as a strategic market due to its healthcare system and regional role in clinical adoption across Southeast Asia, adding that the approval supports regulatory execution and the company’s regional strategy.

Verdye is approved in 41 countries, whilst the IC-Flow imaging system is approved in 45 markets.

UltraGreen.ai also referenced its recent initial public offering and regulatory approval of Verdye in the Philippines as part of its Southeast Asia expansion.

### Related Stocks

- [ULG.SG](https://longbridge.com/en/quote/ULG.SG.md)

## Related News & Research

- [UltraGreen.ai Limited (ULG) Gets a Buy from UOB Kay Hian](https://longbridge.com/en/news/285415825.md)
- [AI face is taking over — and driving plastic surgeons crazy](https://longbridge.com/en/news/286641783.md)
- [11:30 ETDageno Launches Issues Panel and High-volume Prompt Miner to Help Growing Brands Turn AI Search Signals Into Growth Tasks](https://longbridge.com/en/news/286939643.md)
- [06:07 ETStandardC Launches AI Platform for Financial Institutions, Where Customer PII Is Never Shared With AI Models (Patent Pending)](https://longbridge.com/en/news/286892045.md)
- [Singapore Leads Emerging Race to Become World’s First «Trusted AI Financial Hub»](https://longbridge.com/en/news/287063092.md)